Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China

Jia, Yuanxi; Li, Li; Cui, Fuqiang; Zhang, Dongliang; Zhang, Guomin; Wang, Fuzhen; Gong, Xun; Zheng, Hui; Wu, Zhenhua; Miao, Ning; Sun, Xiaojin; Zhang, Li; Lv, Jingjing; Yang, Feng

doi:10.4161/hv.29944

Cited by 33 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, the Chinese government has initiated measures to combat the hepatitis epidemic. For example, free‐of‐charge HBV vaccinations have been provided for all newborns since 2005, and a HBV vaccination “catch‐up” program commenced in 2009 for children aged 8‐15 years . These efforts have markedly reduced the HBV surface antigen (HBsAg) carrier rate in the general population .…”

Section: Introductionmentioning

confidence: 99%

“…For example, free-of-charge HBV vaccinations have been provided for all newborns since 2005, and a HBV vaccination "catch-up" program commenced in 2009 for children aged 8-15 years. 11 These efforts have markedly reduced the HBV surface antigen (HBsAg) carrier rate in the general population. 12,13 To prevent HCV transmission, China enacted a blood donation law in 1998 and implemented a volunteer blood donation system, which further improved the quality of donated blood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China

et al. 2019

View full text Add to dashboard Cite

Background Liver cancer is a commonly diagnosed malignancy in China. The etiologies of liver cancer are widely known, although studies on temporal trends in liver cancer caused by specific etiologies are rare. Methods Data on the incidence and mortality of liver cancer were retrieved from the Global Burden of Diseases Study 2017. The estimated annual percentage change (EAPC) was used to quantify temporal trends in the age‐standardized incidence rate (ASIR) and the age‐standardized mortality rate (ASMR) of liver cancer from 1990 to 2017. Results Nationwide, the number of incident cases of liver cancer increased from 258 000 in 1990 to 515 900 in 2017. The ASIR decreased from 27.16 per 100 000 to 26.04 per 100 000 during this period, with an EAPC of −0.64 (95% confidence interval [CI] −0.84, −0.44). The number of deaths increased from 245 300 in 1990 to 418 200 in 2017, and the ASMR decreased from 26.72 to 21.30 (EAPC = −1.16, 95% CI −1.35, −0.97). The most pronounced decreases in the ASIR and ASMR were observed in liver cancer due to hepatitis B and in people aged 15‐49 years. Conclusions Since the extensive efforts for prevention of hepatitis B virus infection, the incidence of liver cancer due to hepatitis B has significantly decreased. However, liver cancer due to hepatitis C, NASH, and other causes remains a major public health concern. Additional preventive strategies tailored to liver cancer are needed to further reduce its disease burden in China.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Several studies have evaluated the cost-effectiveness of neonatal HBV vaccination, or catch-up vaccination for children or adults in China. All of them have come to the conclusion that primary HBV vaccination given to populations at certain ages is cost-saving, with the incremental cost-effectiveness ratio (ICER) ranging from US$ À13 238/QALY for universal HBV vaccination in Taiwan to US$ À1909/QALY for catch-up vaccination among children/adolescents in China (Hung and Chen, 2009;Hutton et al, 2010;Jia et al, 2014;Lu et al, 2013). The present study is the first to report a cost-effectiveness analysis of booster vaccination for a high-risk population.…”

Section: Discussionmentioning

confidence: 86%

Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China

Wang

Shi

Wang

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objective: In rural areas of China with highly endemic for hepatitis B virus (HBV) infection, protective efficacy was observed in adulthood when a one-dose HBV vaccine booster was administered to high-risk children born to mothers who were positive for hepatitis B surface antigen (HBsAg). The aim of this study was to estimate the cost-effectiveness of an HBV vaccine booster in this specific group of children when given at 10 years of age. Methods: Two potential strategies were considered: strategy 1 was a one-dose booster given if the child was negative on HBsAg screening; strategy 2 was a one-dose booster given if the child was negative on both HBsAg plus anti-HBs screening. A decision tree combined with a Markov model was developed to simulate the booster intervention process and to simulate the natural history of HBV infection in a cohort of 10-year-old children who were born to HBsAg-positive mothers. The model was calibrated based on multiple selected outcomes. Costs and quality-adjusted life years (QALYs) were measured from a societal perspective. Cost-effectiveness ratios (CERs) of the different strategies were compared in both base-case and one-way sensitivity analyses. Results: Compared to the current practice of 'no screening and no booster', both strategy 1 and strategy 2 were cost-saving, with CERs estimated at US$ À6961 and US$ À6872 per QALY gained, respectively. In the one-way sensitivity analysis for strategy 1, all the CERs were found to be less than US$ À5000 per QALY gained after considering the uncertainty of all the variables, including vaccination protective efficacy, natural history, behavior, and various costs and utility weights. In a 'worst case' scenario (all parameter values simultaneously being at the worst), the CER of strategy 1 increased to US$ 3263 per QALY gained, which was still less than the GDP per capita of China in 2016 (US$ 8126). Conclusions: A hepatitis B vaccine booster given to children born to HBsAg-positive mothers in rural China would be cost-effective and could be considered in HBV endemic areas.

show abstract

“…According to Mohammad O Sharif 's recommendation [41], 25 publications were divided into three following groups depending on its total points such as low quality (0-3), medium quality (4-7), and high quality (8)(9)(10)(11).…”

Section: Data Assessmentmentioning

confidence: 99%

“…Some kinds of them can be mentioned as hepatitis A virus (HAV) [5,6], hepatitis B virus (HBV) [7][8][9][10][11], hepatitis C virus (HCV) [12][13][14], hepatitis D virus (HDV) [15], hepatitis E virus (HEV) [16,17], and liver cirrhosis [18]. Thanks to vaccination, people can be prevented from these physical problems and that could lead to reducing a number of infection cases.…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review of Hepatitis Virus Review Studies: A Case of Health Economic Evaluation Analysis

Trần

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Systematic reviews of economic analysis are necessary for assessing reports and making a decision. A systematic review of systematic reviews is mean of summarizing the current evidence across specialties of the same or very similar intervention, to provide a synthesis treatment effect. The aim of this study was to explore and to assess the quality of systematic reviews conducted hepatitis economic evaluation.Methods: This study was designed as a systematic review following the AMSTAR guideline through Medline, Cochrane, and Science Direct databases. It was scoped in publication period of 2001 and 2016 in international journals. The quality assessment of the included studies was based on AMSTAR checklist. Two authors did the appreciation independently and all the different results were solved by discussion to give the conclusion.Results: 851 publications found, only 25 studies of those met the inclusion criteria. These studies consisted of 5 studies for vaccination and 20 for non-vaccination. There were only 16% (n=4) based on PRISMA guideline; and twenty-one studies (64%) were not showing about the method of the systematic review or not based on any guideline. Only three articles has published in 2016 with a high standard. Conclusion:According to the results of the appraisal AMSTAR checklist, this review shows clearly the current situation and an urgent need for an increase of quality of hepatitis virus review studies based on health economic evaluation.

show abstract

Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China

Abstract: The catch-up program in Shandong province among children born between 1994 and 2001 was 'very cost-saving.' It could save life years and reduce total future costs. Our study supported the desirability and impact of such a catch-up program throughout China.

Cited by 33 publications

References 21 publications

Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China

Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China

Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China

A Systematic Review of Hepatitis Virus Review Studies: A Case of Health Economic Evaluation Analysis

Contact Info

Product

Resources

About